SLNO Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Soleno Therapeutics's net margin of --. Soleno Therapeutics's return on equity of -- beat CEL-SCI's return on equity of --.

Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 49.61%. On the other hand CEL-SCI has an analysts' consensus of $7.40 which suggests that it could grow by 2504.72%. Given that CEL-SCI has higher upside potential than Soleno Therapeutics, analysts believe CEL-SCI is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.414%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Soleno Therapeutics's net income of -$56M is lower than CEL-SCI's net income of -$7.1M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,547.46x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Soleno Therapeutics's net margin of -711.67%. Soleno Therapeutics's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 49.61%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1110.94%. Given that IGC Pharma has higher upside potential than Soleno Therapeutics, analysts believe IGC Pharma is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.346%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. Soleno Therapeutics's net income of -$56M is lower than IGC Pharma's net income of -$1.8M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,547.46x versus 18.82x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 49.9%. Soleno Therapeutics's return on equity of -- beat Krystal Biotech's return on equity of 10.49%.

Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 49.61%. On the other hand Krystal Biotech has an analysts' consensus of $214.80 which suggests that it could grow by 14.93%. Given that Soleno Therapeutics has higher upside potential than Krystal Biotech, analysts believe Soleno Therapeutics is more attractive than Krystal Biotech.

Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.870, suggesting its less volatile than the S&P 500 by 12.951%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Krystal Biotech quarterly revenues of $91.1M. Soleno Therapeutics's net income of -$56M is lower than Krystal Biotech's net income of $45.5M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 62.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,547.46x versus 19.10x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Legend Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 14.09%. Soleno Therapeutics's return on equity of -- beat Legend Biotech's return on equity of -15.44%.

Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 49.61%. On the other hand Legend Biotech has an analysts' consensus of $77.92 which suggests that it could grow by 105.37%. Given that Legend Biotech has higher upside potential than Soleno Therapeutics, analysts believe Legend Biotech is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison Legend Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Legend Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Legend Biotech pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Legend Biotech quarterly revenues of $186.5M. Soleno Therapeutics's net income of -$56M is lower than Legend Biotech's net income of $26.3M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Legend Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,547.46x versus 11.06x for Legend Biotech. Usually stocks with elevated PS ratios are considered overvalued.